Products Affected - Description
Vitamin K injection, Amphastar
2 mg/mL, 0.5 mL SAF-T-JET prefilled syringe, 10 count (NDC 76329-1240-01)
Reason for the Shortage
- Amphastar has vitamin K injection on shortage due to increased demand for the product.
- Oral vitamin K is not affected by this shortage.
Vitamin K injection, Hospira
10 mg/mL, 1 mL ampule, 25 count (NDC 00409-9158-01)
2 mg/mL, 0.5 mL ampule, 25 count (NDC 00409-9157-01)
Estimated Resupply Dates
Amphastar has Vitamin K injection on intermittent back order with regular releases
- Avoid off-label oral administration of injectable Vitamin K during the shortage.
- Vitamin K from Amphastar contains polysorbate 80 and propylene glycol.
- Vitamin K from Hospira contains benzyl alcohol.
- Consider reserving Vitamin K injection from Amphastar, which does not contain benzyl alcohol, for neonates and infants.
August 11, June 29, 2015, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins